检测胃癌患者血清中的波形蛋白甲基化。
Detection of vimentin methylation in the serum of patients with gastric cancer.
机构信息
Gastroenterological Surgery, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama 227-8501, Japan.
出版信息
Anticancer Res. 2012 Mar;32(3):791-4.
AIM
Detection of gastric cancer using serum assay of vimentin methylation.
METHODS
A quantitative methylation-specific polymerase chain reaction assay was used to detect vimentin gene (VIM) methylation in the serum of 71 patients with gastric cancer.
RESULTS
Mean VIM methylation in cancer patients (0.304 ± 0.558) was significantly higher than that in healthy donors (0.011 ± 0.015, p=0.018). The sensitivity of VIM methylation (33.8%) was similar to the one of carbohydrate antigen 19-9 (CA19-9) (25.4%), higher than the one of carcinoembryonic antigen (CEA) (12.7%), and significantly higher than the sensitivity of both markers for patients with stage I and IV disease (p=0.010 and 0.044, respectively). At all stages, the sensitivity of a combination of markers was higher than the sensitivity of any in isolation marker and was similar for stages I, II and III, reaching 76.9% for stage IV disease.
CONCLUSION
VIM methylation may represent a useful marker for the detection of tumor DNA in the serum of patients with gastric cancer.
目的
通过血清中波形蛋白甲基化检测来诊断胃癌。
方法
采用定量甲基化特异性聚合酶链反应（PCR）法检测 71 例胃癌患者血清中波形蛋白基因（VIM）甲基化。
结果
胃癌患者的平均 VIM 甲基化水平（0.304±0.558）显著高于健康供者（0.011±0.015，p=0.018）。VIM 甲基化的灵敏度（33.8%）与 CA19-9（25.4%）相似，高于 CEA（12.7%），且对 I 期和 IV 期疾病患者的灵敏度明显高于两种标志物（p=0.010 和 0.044）。在所有分期中，联合标志物的灵敏度均高于单独使用任何一种标志物的灵敏度，且在 I、II 和 III 期相似，对 IV 期疾病的灵敏度达到 76.9%。
结论
VIM 甲基化可能代表了一种用于检测胃癌患者血清中肿瘤 DNA 的有用标志物。
Zotero 插件